Harmony Reynolds, MD, FACC, director of the cardiovascular clinical research center at NYU Langone Health, presented a study at the American College of Cardiology (ACC) 2026 meeting using coronary optical coherence tomography (OCT) and cardiac magnetic resonance imaging (MRI) to determine sex differences in underlying causes of myocardial infarction with no obstructive coronary arteries (MINOCA).

Researchers use multi-modality imaging to learn more about MINOCA

The combination of OCT and MRI can help provide an improved sense of clarity when managing MINOCA patients, according to new data presented at ACC.26 in New Orleans.

 The U.S. Food and Drug Administration (FDA) has granted market clearance for Biotronik's Acticor Sky and Rivacor Sky implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems. The new technology will be launches at the Heart Rhythm Society (HRS) annual meeting this week. #HRS2026

FDA approves 2 implantable heart devices from Biotronik

These devices were built to provide better patient data and improve clinician workflows. They will be on display at Heart Rhythm 2026 in Chicago. 

doctor patient elderly check up hospital

Heart failure experts agree: HFmrEF should not be ignored

Data on the treatment and management of HFmrEF are limited, but a new scientific statement from the Heart Failure Society of America highlights how important it is to take this condition seriously.

Surgeons Operating On Patient

When bioprosthetic mitral valves fail: Redo surgery bests transcatheter treatment after 5 years

Short-term outcomes were comparable, but long-term data revealed a significant difference in all-cause mortality.

cardiologists going through the certification process

Sirolimus- and paclitaxel-coated balloons deliver comparable 1-year PCI outcomes

Researchers explored data from more than 8,000 patients treated over a three-year period. 

Nicholas Marston, MD, MPH assistant professor of medicine, and a cardiologist at Brigham and Women's Hospital, presented the late-breaking VESALIUS-CV data on the use of evolocumab for the reduction of major cardiovascular events in patients who do not have significant atherosclerosis. #ACC26

Evolocumab reduces risk of major cardiac events in diabetic patients

Late-breaking data out of ACC.26 suggest a more aggressive treatment approach for these patients could be beneficial. 

Compensation for U.S. cardiologists is up across the board, according to a recent survey published by MedAxiom, an American College of Cardiology company. The report identified similar trends for cardiovascular surgeons, highlighting the country’s high demand for all heart specialists in 2024 and beyond.

How to prevent the most common complication after heart surgery

The Society of Thoracic Surgeons put together an expert committee to examine the prevention and treatment of new-onset postoperative atrial fibrillation after cardiac surgery. The group shared recommendations for before, during and after treatment.

Heart Rhythm 2025 Heart Rhythm Society President Kenneth A. Ellenbogen, MD

Heart Rhythm 2026 to feature late-breaking EP data, hands-on training and more

Heart Rhythm 2026 in Chicago will include a total of 18 late-breaking clinical trials—and that is just the beginning. The four-day event kicks off April 23.